• Management and coordination of biosimilar projects with global CMC organization• Lead the implementation of Toulouse biosimilar development program

  Coordinated collaboration with Montreal investors and partners Delivered realistic budget plans and strategic perspectives Implemented strategy and led GPCR positive allosteric modulator projects  Initiated interaction with clients (pharmaceuticals and academic labs)

 Led all biology (including experimental design), pharmacology, toxicology, Pharmacokinetic-Pharmacodynamic and biomarker identification activities related to small molecules candidate drug projects (up to clinical Phase II) Coordinated patent redaction in collaboration with AstraZeneca lawyers  Organized collaboration with other AstraZeneca therapeutic areas and external partner (CROs). Accelerated progression of Lead optimization project up to candidate drug nomination and phase I study. Successfully implemented and coordinated collaborations with MedImmune on two antibody drug discovery projects (pain and inflammation)  Implemented fruitful collaborations with key opinion leaders from McGill University, Montreal Neurological Institute, University of Montreal, Indiana University School of Medicine and Sherbrooke University Led the global CNS/Pain/inflammation “Target Validation Network” and in collaboration with other leaders delivered recommendations for improvement to all AstraZeneca therapeutic areas

 Coordinated and managed two successful projects that transitioned to the next milestone (Investigational New Drug (IND) and lead generation). Project documents became a benchmark for the therapeutic area Coached and managed successfully a group of two Ph.D and four master scientists. Established clear challenging but achievable goals with section's input. Led the implementation of native cell assays and systematic label free technology utilization.

 Headed a team of three Ph.D and four masters. Hired one master scientist. Participated to Molecular Science department re-organization.  Championed and provided strategic analysis of a new analgesia target that obtained best ranking. Designed and led successfully High Throughput Screening Campaign.

 Proposed and led one new analgesia project that progressed from target validation to lead identification  As core team member, Molecular Science/pharmacology representative coordinated all the in-vitro assays related to one LO project and accelerated the transition to candidate drug (CD) nomination

 Efficiently managed a team composed of four Ph.D and three masters Led the implementation of two ligand gated ion channels projects As core team member, provided pharmacology and molecular biology expertise to one LO project

 Co-responsible of the establishment and the development of the Ligand Identification for orphan G Protein Coupled Receptors (GPCRs). Received the AstraZeneca R&D Global Scientific and Technical Achievement Award for the deorphanisation of 6 orphan GPCRs that produced four new projects in two different therapeutic areas, coordinated patent redaction in collaboration with AstraZeneca lawyers

Oxytocin and vasopressin receptors regulation